Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2024-11-12 eCollection Date: 2024-01-01 DOI:10.1159/000541988

Kristofoor E Leeuwenberg, Rob Ter Heine, Johanna M M Gijtenbeek, Michel M van den Heuvel

{"title":"Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report.","authors":"Kristofoor E Leeuwenberg, Rob Ter Heine, Johanna M M Gijtenbeek, Michel M van den Heuvel","doi":"10.1159/000541988","DOIUrl":null,"url":null,"abstract":"Introduction: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.Case presentation: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.Conclusion: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1289-1293"},"PeriodicalIF":0.7000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556857/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000541988","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Adagrasib is an upcoming anticancer treatment for KRAS G12C-mutated non-small-cell lung carcinoma, colorectal cancer and potentially other solid tumors harboring this mutation. It is generally well-tolerated and reports of neurological adverse events so far have been limited.

Case presentation: We present to our best knowledge the first case of a 70-year-old woman who was admitted with polyradiculitis as a treatment-related complication of adagrasib. Symptoms resolved after treatment with prednisone and therapy interruption of adagrasib followed by a permanent dose reduction. After the dose reduction, there was an ongoing effective tumor response at follow-up, and serum concentrations of adagrasib remained within the therapeutic index.

Conclusion: Through this case report, we aim to bring attention to the possibility of this side effect, as we believe it is important to be aware of it for future patients undergoing treatment with adagrasib.

查看原文本刊更多论文

与阿达拉西布有关的神经系统并发症--多发性神经炎：病例报告。

简介Adagrasib 是一种即将上市的抗癌治疗药物，用于治疗 KRAS G12C 突变的非小细胞肺癌、结直肠癌以及可能存在这种突变的其他实体瘤。该药的耐受性普遍良好，迄今为止有关神经系统不良事件的报道有限：据我们所知，这是第一例因阿达拉西布治疗相关并发症而患多发性神经根炎的 70 岁女性患者。在接受泼尼松治疗和阿达拉西布治疗中断并永久性减量后，症状得到缓解。减量后，随访时肿瘤反应持续有效，阿达拉西布的血清浓度仍在治疗指数范围内：通过本病例报告，我们希望引起人们对这一副作用可能性的关注，因为我们认为今后接受阿达拉西布治疗的患者必须注意到这一副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊